Companies / Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc.

Nasdaq: NEUPCIK 1191070BURLINGTON, MA

Financials · FY2025

Revenue$15.65M
Net income$-369.6K
Total debt
Cash$19.44M
Diluted EPS$-0.23
Shares outstanding5.4M

Ownership

5.4M shares outstanding · as of May 14, 2026
30.4%Institutions
Ownership
Institutions30.40%1,642,886
Public float69.60%3,761,665

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 4

View all →
Insider% of sharesShares
Fisher AlanDirector
Ryan JaneDirector

Institutional holders 22

View all →

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q1 2026
as of
Balyasny Asset Management L.P.
13F manager
NewCommon Stock$578.7K+142K
142,183
2.63% of shares
low
Q1 2026
as of
Geode Capital Management, LLC
13F manager
AddCommon Stock$141.2K+35K
+200.57%
52,007
0.96% of shares
low
Q1 2026
as of
Bridgeway Capital Management, LLC
13F manager
ExitCommon Stock$-57.2K-15K
-100.00%
0
low
Q2 2026
as of
Persistent Asset Partners Ltd
13F manager
ExitCommon Stock$-52.0K-13K
-100.00%
0
low
Q4 2025
as of
Persistent Asset Partners Ltd
13F manager
AddCommon Stock$33.0K+8K
+173.08%
13,403
0.25% of shares
low
Q4 2025
as of
Bank of America Corp /De
13F manager
AddCommon Stock$4+1
+5.88%
18
<0.01% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Baselake Partners, LPPassive13G/A

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
NEUPCommon StockEquity64136E102BBG01RFZ8658